"Now moving to Slide 6. When you look at how the strategy has translated into operational performance, we see solid operational performance over the past 3 years, with sales growing 5% from USD 42 billion now to approaching USD 49 billion. Core op inc growing double-digit at 10%, exceeding now USD 15 billion. And we've reached our goal \u2013 our initial goal of Innovative Medicines core margin to 35%, on our way to our midterm goal of the high 30s, which we are well on track to achieve."